Henry Schein (HSIC) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HSIC - Henry Schein, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$92.30
DETAILS
HIGH:
$110.00
LOW:
$64.00
MEDIAN:
$94.50
CONSENSUS:
$92.30
UPSIDE:
6.85%
Stock News
Henry Schein Announces Chief Financial Officer Leadership Transition
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that Emmanuel Caprais, former Senior Vice President and Chief Financial Officer of ITT, Inc. (NYSE: ITT), has been named the Company's Senior Vice President and Chief Financial Officer effective November 4, 2026. Mr. Caprais will join the Henry Schein Leadership Team (HSLT) and report to Frederick M. Lowery, Chief Executive Officer of Henry Schein. To support a structured transition, Mr. Caprais will initially se.
HSIC or MMSI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?
Should Value Investors Buy Henry Schein (HSIC) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Henry Schein Cares Marks 25 Years of Helping Health Happen®
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Cares, Henry Schein, Inc.'s global corporate citizenship program, is celebrating a quarter century of bringing together Team Schein Members, customers, supplier partners, healthcare professionals, nonprofit organizations, and communities to help make the world healthier. Today, Henry Schein Cares reflects the Company's broader approach to corporate citizenship through five interconnected pillars: Catalyzing Healthcare Access; Advancing Policies, Sol.
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher
Henry Schein remains a dominant global provider of dental and medical practitioner supplies, with recent share price outperformance versus the S&P 500. HSIC delivered strong Q2 results: revenue up 6.7% to $3.46B, net income and cash flow both meaningfully improved, and all business segments showed growth. Management raised 2026 guidance, now expecting 4.5–5.5% revenue growth and adjusted EPS of $5.29–$5.39, reflecting ongoing operational momentum.
Are Investors Undervaluing Henry Schein (HSIC) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What Makes Henry Schein (HSIC) a New Buy Stock
Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HSIC or SAUHY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why Henry Schein (HSIC) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein: Growth Is Improving, But The Valuation Stays Cheap
Henry Schein is rated buy with a 12-month price target of $104, reflecting accelerating organic growth, margin expansion, and substantial share repurchases. Q2 2026 results showed 4.6% internal growth, 48 bps gross margin expansion, and a 6.7% reduction in diluted share count, signaling improved business quality. The BOLD+1 cost program targets $125M+ in annual run-rate operating income gains by end-2026, supporting double-digit earnings growth potential into 2027.
Henry Schein, Inc. (HSIC) Presents at 2026 Global Healthcare Conference Transcript
Henry Schein, Inc. (HSIC) Presents at 2026 Global Healthcare Conference Transcript
Applied BioCode Announces Distribution Agreement with Henry Schein
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- #ClinicalDiagnostics--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services, to expand the availability of its BioCode® MDx-3000 System and comprehensive molecular diagnostics menu. The BioCode® MDx-3000 is an automated, high-throughput multiplex molecular diagnostic platform designed to support high-complexity clinical laboratories. Its testing menu includes upper respiratory and gastrointestinal.
Henry Schein to Participate in Upcoming Investor Conference in September
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conference in September: Baird Global Healthcare Conference at the InterContinental Hotel, New York City on September 15, 2026, at 12:15 p.m. EDT. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on t.
Henry Schein (HSIC) is an Incredible Growth Stock: 3 Reasons Why
Henry Schein (HSIC) could produce exceptional returns because of its solid growth attributes.
Why Is Henry Schein (HSIC) Up 0.9% Since Last Earnings Report?
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Henry Schein (HSIC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
505,999 Shares in Henry Schein, Inc. $HSIC Purchased by Bank of New York Mellon Corp
Bank of New York Mellon Corp purchased a new stake in Henry Schein, Inc. (NASDAQ: HSIC) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 505,999 shares of the company's stock, valued at approximately $42,261,000. Bank of New York
Price Targets
Henry Schein price target lowered to $92 from $96 at Leerink
$92.00
(was $84.98)
Leerink Partners
Henry Schein price target raised to $110 from $100 at BTIG
$110.00
(was $90.61)
David Larsen
·
BTIG
Henry Schein price target raised to $100 from $86 at Barclays
$100.00
(was $89.59)
Barclays
Henry Schein price target raised to $104 from $97 at Barrington
$104.00
(was $89.11)
Michael Petusky
·
Barrington
Henry Schein price target raised to $94 from $89 at UBS
$94.00
(was $89.11)
Kevin Caliendo
·
UBS
Henry Schein price target raised to $95 from $84 at Stifel
$95.00
(was $89.11)
Stifel Nicolaus
Henry Schein price target raised to $89 from $85 at UBS
$89.00
(was $85.88)
UBS
Henry Schein initiated with a Market Perform at BMO Capital
$85.00
(was $83.22)
Vik Chopra
·
BMO Capital
BTIG upgrades Henry Schein to Buy on 'healthy' dental markets
$100.00
(was $78.85)
BTIG
Henry Schein price target lowered to $85 from $87 at UBS
$85.00
(was $74.35)
Kevin Caliendo
·
UBS
Henry Schein price target lowered to $82 from $88 at Mizuho
$82.00
(was $74.37)
Mizuho Securities
Henry Schein price target lowered to $97 from $104 at Baird
$97.00
(was $74.37)
Robert W. Baird
Henry Schein price target raised to $64 from $61 at Morgan Stanley
$64.00
(was $78.22)
Erin Wright
·
Morgan Stanley
Henry Schein price target raised to $97 from $79 at Barrington
$97.00
(was $81.60)
Barrington
Henry Schein price target raised to $87 from $75 at Leerink
$87.00
(was $83.35)
Leerink Partners
Henry Schein upgraded to Outperform from Neutral at Baird
$100.00
(was $79.57)
Robert W. Baird
Henry Schein price target raised to $81 from $74 at Mizuho
$81.00
(was $79.98)
Steven Valiquette
·
Mizuho Securities
Henry Schein initiated with an Overweight at Barclays
$86.00
(was $72.86)
Barclays
Henry Schein price target raised to $90 from $83 at Evercore ISI
$90.00
(was $71.69)
Evercore ISI
Henry Schein price target raised to $79 from $78 at Barrington
$79.00
(was $71.32)
Barrington